Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BriaCell Therapeutics Corp.BCTX · Entity 7454 | Director | August 01, 2022 | August 01, 2022 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BriaCell Therapeutics Corp.
Report date August 01, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2026-03-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-08-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.47 · Expires 2027-01-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-08-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Option vests quarterly for 2 years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option vests quarterly for 2 years from the date of grant.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 452,667 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 452,667 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F3: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Common StockSEC Table I · non-derivative | IndirectBy SQN LLC | 655,540 |
Reported balance
Holding disclosure · report date 2026-06-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 655,540 F2: The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2025 Filed Dec 12, 2025 21:35 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 18,650 | $15.80 | $294,670.00 |
DisclosureSEC source: 0001628280-25-056792 · wk-form4_1765575309.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 43,263 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · derivative · entry 17 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,263 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 700 | $359.71 | $251,797.56 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 14 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,044 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.51 to $359.78, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,541 | $358.81 | $2,346,982.75 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 13 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,744 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.44 to $359.43, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,715 | $357.85 | $2,402,981.55 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 12 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 468,285 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.44 to $358.43, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,864 | $356.88 | $1,735,861.40 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 11 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 475,000 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.44 to $357.41, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,752 | $355.95 | $2,047,436.48 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 10 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,864 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.44 to $356.43, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,479 | $354.97 | $2,299,873.31 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 9 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 485,616 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.44 to $355.43, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,587 | $354.04 | $1,623,997.08 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 8 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 492,095 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.43 to $354.42, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,175 | $352.45 | $414,130.40 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 7 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 496,682 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.17 to $353.01, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,870 | $351.60 | $1,009,090.85 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 6 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 497,857 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.16 to $352.12, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,580 | $350.87 | $1,256,127.13 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 5 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 500,727 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.10 to $351.08, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 43,263 | $9.45 | $408,835.35 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 4 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 504,307 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,200 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · derivative · entry 16 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,263 Underlying: Common Stock · 3,200 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 220 | $351.02 | $77,224.80 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 3 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,044 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.00 to $351.24, inclusive. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,980 | $350.18 | $1,043,528.35 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 2 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,264 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:33 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 3,200 | $9.45 | $30,240.00 |
DisclosureSEC source: 0001423898-25-000005 · wk-form4_1755120803.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001628280-25-035583 · wk-form4_1753218526.xml · derivative · entry 4 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,463 Underlying: Common Stock · 1,000 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $350.01 | $350,005.00 |
DisclosureSEC source: 0001628280-25-035583 · wk-form4_1753218526.xml · nonDerivative · entry 2 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,044 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:08 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 1,000 | $9.45 | $9,450.00 |
DisclosureSEC source: 0001628280-25-035583 · wk-form4_1753218526.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,657 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · derivative · entry 14 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,463 Underlying: Common Stock · 2,657 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 600 | $351.50 | $210,898.02 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 11 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,044 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.17 to $352.00, inclusive. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,057 | $350.09 | $720,136.78 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 10 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,644 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.61, inclusive. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 2,657 | $9.45 | $25,108.65 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 9 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,444 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · derivative · entry 13 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,120 Underlying: Common Stock · 26,444 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,380 | $356.52 | $492,004.22 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 8 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,044 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.18 to $356.90, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,441 | $355.61 | $2,290,499.47 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 7 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,424 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.12 to $356.11, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,800 | $354.61 | $2,056,738.00 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 6 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 468,865 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.12 to $355.09, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,569 | $353.82 | $908,963.32 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 5 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,665 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.12 to $354.11, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,357 | $352.64 | $831,170.12 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 4 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,234 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.00 to $352.99, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,897 | $351.37 | $666,546.42 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 3 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,591 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.00 to $351.96, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,000 | $350.19 | $2,101,141.80 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 2 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 481,488 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 26,444 | $9.45 | $249,895.80 |
DisclosureSEC source: 0001628280-25-035340 · wk-form4_1752869497.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 487,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 22:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 7,381 | $0.00 Strike: $347.28 | $0.00 |
DisclosureSEC source: 0001628280-25-011359 · wk-form4_1741384821.xml · derivative · entry 3 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,381 Underlying: Common Stock · 7,381 shares Expires 2035-03-05 F3 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 22:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 4,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011359 · wk-form4_1741384821.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,044 F1 · kind: 1. Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 22:07 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 648 | $335.24 | $217,235.52 |
DisclosureSEC source: 0001628280-25-002658 · wk-form4_1738015664.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,662 F1 · kind: The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| January 17, 2025 Filed Jan 18, 2025 00:05 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,689 | $273.41 | $461,789.49 |
DisclosureSEC source: 0001628280-25-001898 · wk-form4_1737158698.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 457,310 F1 · kind: The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,676 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0000950170-24-043503 · ownership.xml · derivative · entry 9 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,564 Underlying: Common Stock · 2,676 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 200 | $248.58 | $49,716.00 |
DisclosureSEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 7 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,999 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.57 to $248.59, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 407 | $247.76 | $100,837.59 |
DisclosureSEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 6 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,199 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.56 to $248.5150, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 600 | $246.98 | $148,186.38 |
DisclosureSEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 5 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,606 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.50 to $247.25, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 300 | $245.69 | $73,706.01 |
DisclosureSEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 4 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,206 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.38 to $246.13, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 945 | $244.79 | $231,324.75 |
DisclosureSEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 3 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,506 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.37 to $245.24, inclusive. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 224 | $243.25 | $54,486.88 |
DisclosureSEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 2 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,451 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.12 to $243.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 00:53 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 2,676 | $9.45 | $25,288.20 |
DisclosureSEC source: 0000950170-24-043503 · ownership.xml · nonDerivative · entry 1 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,506 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0000899243-24-000266 · doc4.xml · derivative · entry 26 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,240 Underlying: Common Stock · 27,506 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F20 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,278 | $245.53 | $1,295,924.23 |
DisclosureSEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 22 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,999 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.03 to $245.88, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,079 | $244.45 | $508,213.42 |
DisclosureSEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 21 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,277 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.03 to $245.02, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 8,989 | $243.33 | $2,187,287.98 |
DisclosureSEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 20 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,356 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.00 to $243.95, inclusive. Read SEC document |
| April 05, 2024 Filed Apr 6, 2024 00:50 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 8,817 | $242.61 | $2,139,068.56 |
DisclosureSEC source: 0000899243-24-000266 · doc4.xml · nonDerivative · entry 19 Taub Rebecca · CIK 0001423898 · Director · Pres., R&D, and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 475,345 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.00 to $242.99, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.